UK-based immersive technology company FourPlus has secured funding from Innovate UK, the UK’s national innovation agency, to develop a mixed reality training platform for pharmaceutical companies and the healthcare sector. FourPlus already uses its immersive technology, including virtual reality experiences, in the life sciences sector for marketing, training, and workforce management. With a ₤1 million investment, the company will collaborate with Holosphere and the Cell and Gene Therapy Catapult to create a mixed reality experience with multiplayer capabilities, targeting manufacturing roles in cell and gene therapy and the broader life sciences industry. The platform will enable training, store digital training records, provide data analytics tools, and facilitate trainer/trainee collaboration in virtual environments. The 18-month project is expected to have its first release available for demonstration by the end of 2023.
The use of extended reality (virtual, augmented, and mixed reality) is growing in the healthcare industry. German company apoQlar recently received FDA clearance for its VSI HoloMedicine platform, which uses mixed reality technology to help surgeons plan procedures using 3D holographic images. Augmedics, an augmented reality platform, raised $82.5 million in Series D funding for its xvision Spine System, which offers surgeons a 3D view of a patient’s spinal anatomy during surgery. Other companies in the immersive technology space include AppliedVR, Osso VR, MyndVR, XRHealth, and Healium, all of which are leveraging virtual and augmented reality for therapeutic purposes in various healthcare applications.
July 10, 2023
Artificial Intelligence
FDAcop
